Disciplined Growth Investors Inc Cara Therapeutics, Inc. Transaction History

Disciplined Growth Investors Inc

$4.73 Billion
Q3 2024

A detailed history of Disciplined Growth Investors Inc transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Disciplined Growth Investors Inc holds 1,113,043 shares of CARA stock, worth $467,478. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,113,043

Previous 1,935,718 42.5%

Holding current value

$467,478

Previous $503,000 31.41%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.26 - $0.38 $213,895 - $312,616	-822,675 Reduced 42.5%	1,113,043 $345,000
Q2 2024 Aug 15, 2024	BUY	$0.24 - $0.92 $28,958 - $111,007	120,660 Added 6.65%	1,935,718 $503,000
Q1 2024 May 15, 2024	BUY	$0.52 - $1.05 $1,538 - $3,105	2,958 Added 0.16%	1,815,058 $1.65 Million
Q4 2023 Feb 14, 2024	BUY	$0.6 - $1.65 $23,821 - $65,509	39,703 Added 2.24%	1,812,100 $1.34 Million
Q3 2023 Nov 14, 2023	BUY	$1.67 - $3.33 $13,687 - $27,292	8,196 Added 0.46%	1,772,397 $2.98 Million
Q2 2023 Aug 14, 2023	BUY	$2.83 - $4.94 $90,067 - $157,220	31,826 Added 1.84%	1,764,201 $4.99 Million
Q1 2023 May 15, 2023	BUY	$4.89 - $12.27 $48,577 - $121,890	9,934 Added 0.58%	1,732,375 $8.51 Million
Q4 2022 Feb 14, 2023	BUY	$8.88 - $12.77 $197,233 - $283,634	22,211 Added 1.31%	1,722,441 $18.5 Million
Q3 2022 Nov 15, 2022	BUY	$8.24 - $12.56 $11,601 - $17,684	1,408 Added 0.08%	1,700,230 $15.9 Million
Q2 2022 Aug 15, 2022	BUY	$7.45 - $13.84 $33,316 - $61,892	4,472 Added 0.26%	1,698,822 $15.5 Million
Q1 2022 May 16, 2022	BUY	$9.94 - $12.65 $372,640 - $474,235	37,489 Added 2.26%	1,694,350 $20.6 Million
Q4 2021 Feb 14, 2022	SELL	$11.99 - $18.14 $146,613 - $221,815	-12,228 Reduced 0.73%	1,656,861 $20.2 Million
Q3 2021 Nov 15, 2021	BUY	$11.55 - $16.06 $11.5 Million - $16 Million	994,243 Added 147.33%	1,669,089 $25.8 Million
Q2 2021 Aug 16, 2021	BUY	$12.38 - $29.19 $1.01 Million - $2.37 Million	81,363 Added 13.71%	674,846 $9.63 Million
Q1 2021 May 17, 2021	SELL	$15.07 - $21.71 $1.45 Million - $2.09 Million	-96,416 Reduced 13.98%	593,483 $12.9 Million
Q4 2020 Feb 16, 2021	SELL	$12.72 - $16.16 $552,658 - $702,119	-43,448 Reduced 5.92%	689,899 $10.4 Million
Q3 2020 Nov 16, 2020	BUY	$12.34 - $17.92 $12,340 - $17,920	1,000 Added 0.14%	733,347 $9.33 Million
Q2 2020 Aug 14, 2020	SELL	$12.39 - $17.33 $299,726 - $419,230	-24,191 Reduced 3.2%	732,347 $12.5 Million
Q1 2020 May 15, 2020	SELL	$9.12 - $17.78 $751,269 - $1.46 Million	-82,376 Reduced 9.82%	756,538 $9.99 Million
Q4 2019 Feb 14, 2020	BUY	$16.11 - $25.98 $853 - $1,376	53 Added 0.01%	838,914 $13.5 Million
Q3 2019 Nov 15, 2019	BUY	$18.28 - $26.91 $10,657 - $15,688	583 Added 0.07%	838,861 $15.3 Million
Q2 2019 Aug 14, 2019	SELL	$17.68 - $21.57 $258,375 - $315,223	-14,614 Reduced 1.71%	838,278 $18 Million
Q1 2019 May 14, 2019	BUY	$14.41 - $19.64 $79,384 - $108,196	5,509 Added 0.65%	852,892 $16.7 Million
Q4 2018 Feb 13, 2019	SELL	$12.45 - $23.47 $28,622 - $53,957	-2,299 Reduced 0.27%	847,383 $11 Million
Q3 2018 Nov 16, 2018	SELL	$17.57 - $23.95 $151,189 - $206,089	-8,605 Reduced 1.0%	849,682 $20.4 Million
Q2 2018 Aug 15, 2018	SELL	$11.6 - $19.27 $14,824 - $24,627	-1,278 Reduced 0.15%	858,287 $16.4 Million
Q1 2018 May 17, 2018	SELL	$11.77 - $16.08 $19,467 - $26,596	-1,654 Reduced 0.19%	859,565 $10.6 Million
Q4 2017 Feb 15, 2018	BUY	$11.86 - $14.08 $143,138 - $169,931	12,069 Added 1.42%	861,219 $10.5 Million
Q3 2017 Nov 14, 2017	BUY	$12.6 - $16.34 $10.7 Million - $13.9 Million	849,150	849,150 $11.6 Million

Others Institutions Holding CARA

# of Institutions

Shares Held

12.8M

Call Options Held

Put Options Held

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $22.6M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Disciplined Growth Investors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Disciplined Growth Investors Inc with notifications on news.

Account

Disciplined Growth Investors Inc Cara Therapeutics, Inc. Transaction History